A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme
Φόρτωση...
Ημερομηνία
Συγγραφείς
Groves, M. D.
Maor, M. H.
Meyers, C.
Kyritsis, A. P.
Jaeckle, K. A.
Yung, W. K.
Sawaya, R. E.
Hess, K.
Bruner, J. M.
Peterson, P.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Int J Radiat Oncol Biol Phys
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
PURPOSE: To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme. METHODS AND MATERIALS: Between 1994 and 1996, 88 patients were enrolled to receive 1.9 Gy of radiation three times a day for two 5-day cycles separated by 2 weeks; each 5-day cycle was preceded by a continuous 96-hour infusion of BrdU at a dose of 2.1 g/m2/day. After radiotherapy, patients received PCV chemotherapy. RESULTS: Median survival for all 88 patients was 50 weeks. Seventy (79.5 %) received one or more courses of PCV; their median survival was 57 weeks. Covariates predictive of improved survival were gross total versus subtotal resection or biopsy (p = 0.0048) and radiation dose > or = 56 Gy (p = 0.019). While receiving BrdU, 47 patients (53%) suffered grade 3 or 4 thrombocytopenia or leukopenia; 22 patients (25%) suffered grade 3 or 4 dermatologic toxicity. CONCLUSION: Survival was not extended in patients with glioblastoma or gliosarcoma who received BrdU at the dose and administration schedule used in this study. The BrdU dose used in this study resulted in substantial myelosuppressive and dermatologic toxicity.
Περιγραφή
Λέξεις-κλειδιά
Adult, Aged, Antimetabolites, Antineoplastic/administration & dosage/adverse effects, Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse, effects, Brain Neoplasms/*drug therapy/pathology/*radiotherapy/surgery, Bromodeoxyuridine/administration & dosage/adverse effects, Cognition/drug effects/radiation effects, Combined Modality Therapy, Disease Progression, Disease-Free Survival, Female, Glioblastoma/*drug therapy/pathology/*radiotherapy/surgery, Humans, Lomustine/administration & dosage/adverse effects, Male, Middle Aged, Procarbazine/administration & dosage/adverse effects, Radiation-Sensitizing Agents/*administration & dosage/adverse effects, Reoperation, Vincristine/administration & dosage/adverse effects
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/10477016
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής